We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
-17.92%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$999M
AUM Growth
-$111M
Cap. Flow
+$163M
Cap. Flow %
16.29%
Top 10 Hldgs %
53.54%
Holding
68
New
18
Increased
13
Reduced
17
Closed
15

Top Buys

1
ARGX icon
argenx
ARGX
+$73.3M
2
XNCR icon
Xencor
XNCR
+$36.3M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$33.3M
4
SLDB icon
Solid Biosciences
SLDB
+$27.2M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$25.8M

Top Sells

1
MGNX icon
MacroGenics
MGNX
+$31.8M
2
ASND icon
Ascendis Pharma A/S
ASND
+$25.6M
3
KYNB
Kyntra Bio
KYNB
+$22.2M
4
SRRK icon
Scholar Rock
SRRK
+$20.2M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$19.4M

Sector Composition

1 Healthcare 77.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
26
CALL
DELISTED
Celgene Corp
CELG
$12.5M 1.25%
195,000
-5,000
-3% -$369K
IRWD icon
27
CALL
Ironwood Pharmaceuticals
IRWD
$640M
$12.1M 1.22%
1,399,726
+722,012
+107% +$8.29M
MYOK
28
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$11.5M 1.15%
+234,381
New +$12.9M
RYTM icon
29
Rhythm Pharmaceuticals
RYTM
$7.26B
$10.8M 1.08%
+400,838
New +$11.1M
NKTR icon
30
CALL
Nektar Therapeutics
NKTR
$2.3B
$10.4M 1.04%
21,113
-554
-3% -$334K
WVE icon
31
Wave Life Sciences
WVE
$1.11B
$9.84M 0.98%
233,933
+189,092
+422% +$8.41M
SURF
32
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$9.59M 0.96%
2,261,328
+897,849
+66% +$6.93M
RUBY
33
DELISTED
Rubius Therapeutics, Inc
RUBY
$9.52M 0.95%
592,128
– –
ARRY
34
DELISTED
Array Biopharma Inc
ARRY
$9.18M 0.92%
+644,002
New +$9.77M
PRTA icon
35
Prothena Corp
PRTA
$456M
$8.63M 0.86%
+838,219
New +$9.96M
DNTH icon
36
Dianthus Therapeutics
DNTH
$5.67B
$7.86M 0.79%
86,218
-9,913
-10% -$1.35M
IMDZ
37
DELISTED
Immune Design Corp.
IMDZ
$7.28M 0.73%
5,603,191
+3,361,291
+150% +$5.84M
RCKT icon
38
Rocket Pharmaceuticals
RCKT
$373M
$6.67M 0.67%
+450,000
New +$7.47M
CRSP icon
39
CRISPR Therapeutics
CRSP
$4.71B
$5.97M 0.6%
208,850
-291,150
-58% -$10.1M
NGNE icon
40
Neurogene
NGNE
$752M
$4.89M 0.49%
113,294
– –
PTLA
41
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$4.84M 0.48%
+247,858
New +$5.1M
ACRS icon
42
Aclaris Therapeutics
ACRS
$792M
$4.54M 0.45%
+613,728
New +$6.33M
FPRX
43
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$3.04M 0.3%
+326,775
New +$3.89M
CORT icon
44
Corcept Therapeutics
CORT
$9.64B
$2.22M 0.22%
+166,005
New +$2.19M
CRIS icon
45
Curis
CRIS
$8.95M
$2.06M 0.21%
+7,456
New +$4.08M
DVAX
46
DELISTED
Dynavax Technologies
DVAX
$1.28M 0.13%
+140,118
New +$1.55M
CHMA
47
DELISTED
Chiasma, Inc. Common Stock
CHMA
$1.18M 0.12%
379,753
– –
CRVS icon
48
Corvus Pharmaceuticals
CRVS
$1.27B
$1.08M 0.11%
295,420
-55,981
-16% -$382K
TRAW icon
49
Traws Pharma
TRAW
$10.3M
$893K 0.09%
1,129
-204
-15% -$348K
ARVN icon
50
Arvinas
ARVN
$524M
$643K 0.06%
50,000
– –
1
2
3

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
CPC
Cookson Peirce & Co Pittsburgh, Pennsylvania $2.36B AUM 68.36% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return

EcoR1 Capital's Q4 2018 Portfolio in Review

As of Q4 2018, EcoR1 Capital held 68 positions worth $999M, down 10% from $1.11B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

EcoR1 Capital deployed $163M of net new capital in Q4 2018, opening 18 new positions and adding to 13 existing holdings. Its largest new stake was argenx: 825,087 shares worth $79.3M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 77% a quarter earlier.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $25.6M trimmed.

  • EcoR1 Capital's largest Q4 2018 buy was argenx: 825,087 shares worth $79.3M.
  • EcoR1 Capital added most to Ionis Pharmaceuticals in Q4 2018, an estimated $33.3M increase.
  • EcoR1 Capital's biggest Q4 2018 reduction was Ascendis Pharma A/S, cutting an estimated $25.6M.
  • EcoR1 Capital fully exited MacroGenics in Q4 2018, selling an estimated $31.8M.
  • EcoR1 Capital's ten largest holdings make up 54% of its $999M portfolio in Q4 2018.
  • EcoR1 Capital opened 18 new positions and closed 15 in Q4 2018.
  • EcoR1 Capital's portfolio value fell 10% quarter-over-quarter to $999M.

Based on EcoR1 Capital's 13F filing for Q4 2018, filed 14 Feb 2019.